Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_assertion type Assertion NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_head.
- NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_assertion description "[In a hospital-based, case-control study of 830 non-Hispanic white patients with SCCHN and 854 cancer-free, matched control participants, the authors genotyped the ADPRT alanine 762 valine (Ala762Val) single-nucleotide polymorphism (SNP), the XRCC1 arginine 399 glutamine (Arg399Gln) SNP, and the APE aspartic acid 148 glutamic acid (Asp148Glu) SNP and assessed their associations with the risk of SCCHN in multivariate logistic regression models.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_provenance.
- NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_assertion evidence source_evidence_literature NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_provenance.
- NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_assertion SIO_000772 17614107 NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_provenance.
- NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_assertion wasDerivedFrom befree-20140225 NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_provenance.
- NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_assertion wasGeneratedBy ECO_0000203 NP321270.RAgELqM34i39PzU2eG7q52_WGUuLbxUkGSH3Hrm1GglN8130_provenance.